Using a transient expression assay in Vero cells, we have shown that the protein product from gene 61 of varicella-zoster virus (VZV) can repress the function of the VZV encoded trans-activators on putative viral immediate-early, early, and late gene promoters. The repression is exerted at the transcriptional level and requires functional gene 61 protein. This trans-repressor is the herpes simplex type 1 ICPO (a trans-activator) homolog, as defined by gene location, the sharing of a cysteine-rich putative zinc-binding finger in the amino-terminal region, and limited amino acid homology. Open reading frame 61 (ORF61)-mediated trans-repression appears to be specific for VZV-encoded trans-activators in that it has no effect on simian virus 40 and Rous sarcoma virus promoters. Moreover, it does not inhibit trans-activation of the human T-lymphotropic virus type I and human immunodeficiency virus long terminal repeats by tax and tat genes, respectively. We constructed plasmids with mutations in ORF61 and tested them for their ability to inhibit trans-activator (VZV genes 4 and 62)-mediated activation of the viral thymidine kinase promoter-chloramphenicol acetyltransferase construct. Mutants containing interruptions in ORF61 lost their trans-repressing ability, as demonstrated at both the protein and steady-state RNA levels. These results suggest that the ORF61 protein product can mediate down-regulation of VZV gene expression.
The control of gene transcription is brought about either by the direct interaction of trans-acting proteins with cisacting promoter elements (20) or by the interaction of trans-acting proteins with cellular factors. The newly formed complexes, in turn, bind to the cis-acting DNA elements (13, 28, 31, 36) . A number of viral trans-acting proteins have been shown to be important for the expression of different classes of viral genes. Simian virus 40 (SV40) large T antigen has both repressor and activator functions. It negatively regulates SV40 early gene transcription and positively regulates late gene expression (16, 21, 29, 38, 45) . Adenovirus codes for a regulatory gene, Ela, whose products stimulate the adenovirus early promoters (1, 24, 39) . Adenovirus Ela products also have repressor activity, since they repress the activity of SV40, polyomavirus, and adenovirus type 2 Ela enhancers (2, 46) . Herpesviruses offer more complexity in regulation because they harbor a bigger genome, with herpes simplex virus type 1 (HSV-1) coding for at least three immediate-early regulatory proteins, ICPO, ICP4, and ICP27. Among these, ICP0 and ICP4 have been shown to trans-activate various viral promoters (5, 8, 9, 11, 27, 32, 33, 37, 42) . ICP27 has been shown to be a trans-repressor or trans-activator in combination with HSV-1 trans-inducing genes ICP4 and ICPO (41) . Synergistic trans-activation of HSV early gene expression by ICP4 and ICP0 has been demonstrated (8, 9, 11, 27, 32, 37) , suggesting a possible interaction between ICP4 and ICPO. Therefore, HSV immediate-early gene products may interact with each other in order to perform their functions. A similar type of interaction has been envisioned for the products of ICP27 and those of ICP4 and ICP0 (41) , resulting in either transcriptional activation or repression, depending on the target promoter.
In our laboratory, we have mapped putative immediateearly trans-activating genes of varicella-zoster virus (VZV) to products of gene 4 and gene 62 (17) . Open reading frame 4 (ORF4) and HSV-1 ICP27 share amino acid homology (4), but functionally it is not clear how they are related. ORF62 is the ICP4 homolog, as shown at the amino acid level as well as functionally (4, 10) . Both of these VZV regulatory genes act at the level of transcription and synergistically activate the expression of putative immediate-early and late gene promoters (17) .
We present here the identification of a VZV trans-repressor gene to ORF61, whose protein product can downregulate the stimulation of viral putative immediate-early, early, and late promoters by the VZV trans-activator genes 4 and 62. Our results suggest that the ORF61 protein product interacts with ORF4 and ORF62, thus resulting in ORF61-mediated trans-repression. This trans-repression occurs at the level of RNA. Additionally, the ORF61 product represses, in trans, the activation of the human immunodeficiency virus (HIV) long terminal repeat (LTR) by ORF4 and ORF62. Deletion and insertion mutants of ORF61 no longer possess the trans-repressing ability. ORF61 alone had no effect on the expression of these target genes.
MATERIALS AND METHODS
Cells and viruses. Vero cells (American Type Culture Collection, Rockville, Md.) were maintained in minimal essential medium and medium 199 (1:1) supplemented with 10% heat-inactivated fetal bovine serum, 2 mM glutamine, penicillin G (100 U/ml), and streptomycin (100 ,ug/ml). Stocks of VZV Ellen strain were propagated, and titers were determined in Flow 5000 cells as previously described (44 (Fig. 1) . According to the DNA sequence, ORF61 is 1.4 kb and codes for 467 amino acid residues (4). The construction of pGORF4-CAT is shown in Fig. 1 carries an internal deletion of 229 amino acids, leaving ORF60 intact. Construction of plasmids LTR-CAT and pSV2tat has been described elsewhere (12) ; tax and human T-lymphotropic virus type I (HTLV-I)-LTR-CAT constructs were a generous gift from K.-T. Jeang (19, 30, 43 analysis have been described previously (35) . RNA molecular weight markers (Bethesda Research Laboratories) used in each experiment were visualized by ethidium bromide staining. For slot blot, Vero cells were seeded in 150-mm dishes and transfected as described. Forty-eight hours posttransfection, total cellular RNA was extracted by the guanidinium isothiocyanate-cesium chloride method (3). Slot blots were performed as described earlier (17) .
Primer extension analysis. Primer extension analysis of ORF61 RNA was conducted by using a 20-base synthetic primer (5'-TCCATGGTAACAACTGGCTG-3') complementary to nucleotides +5 to -15 relative to the AUG of ORF61. One-half nanogram of labeled primer was hybridized to 30 ,ug of total cellular RNA from either uninfected or VZVinfected MRC-5 cells. Hybridization and subsequent reverse transcription were carried out as described previously (40), and reaction products were resolved by electrophoresis in 8% polyacrylamide gels containing 8 M urea.
In vitro transcription and translation of ORF61. Plasmid DNAs (10 ,ug each) carrying ORF61 and ORF61-i3 (purified by equilibrium centrifugation in cesium chloride) were digested with StuI (923 bp downstream of the 3' stop codon), treated with proteinase K (1 mg/ml solution), phenol-chloroform extracted, and ethanol precipitated. To synthesize 5' capped RNA, the linearized DNA template was transcribed in vitro by using an mRNA capping kit (Stratagene Cloning Systems, La Jolla, Calif.). RNA was purified by phenolchloroform extraction and ethanol precipitation and resuspended in 10 ,ul of RNase-free TE buffer (10 mM Tris HCI [pH 7.5], 1 mM EDTA). One-fourth of the in vitro-transcribed RNA was translated in vitro, using a rabbit reticulocyte lysate with 50 p.Ci of [35S]methionine. Labeled translated proteins were analyzed by 4 to 20% gradient sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) as described by Laemmli (22) . A prestained protein mixture (Sigma) was used for molecular weight standards. After electrophoresis, the gel was fixed with 10% acetic acid-30% methanol, treated with Amplify (a fluorographic reagent; Amersham), dried, and autoradiographed for 4 h.
RESULTS
trans-activation of VZV putative immediate-early, early, and late promoters by ORF4 and ORF62. Two previously mapped VZV trans-activating genes, 4 and 62 (17) Fig. 2 . Both trans-activators were able to induce the expression of all three types of promoter-CAT constructs. ORF4 and ORF62 stimulated the expression of pORF4-CAT 3-and 7-fold, respectively (Fig.  2, lanes 2 and 3) , that of pORF68-CAT 2-and 6-fold, respectively (Fig. 2, lanes 6 and 7) , and that of pltk-CAT 17 served when pGORF4 and pGi26 (gene 62) were used together in cotransfection assays. Cotransfection of pGORF4 and pGi26 (ORF62) along with either pORF4-CAT or pORF68-CAT resulted in 83-and 22-fold increases in the CAT activity, respectively (Fig. 2, lanes 4 and 8) .
Gene 61 inhibits the trans-activation of all classes of VZV promoters by ORF4 and ORF62. We have previously reported that clone p29 contains a trans-repressing activity because of its ability to down-regulate the activation of pltk-CAT by ORF4 and ORF62 (17) . Nucleotide sequence analysis of the virus indicates that plasmid p29 contains two ORFs, ORF60 and ORF61. To delineate the trans-repressor activity, we subcloned gene 61 as a single copy on a plasmid and used that plasmid in transient cotransfection assays to test its ability to down-regulate ORF4-and ORF62-mediated trans-activation of VZV putative immediate-early, early, and late promoter constructs. pORF62, pGORF4, and a combination of pGORF4 and pORF62 stimulated the expression of pltk-CAT by 9-, 10-, and 13-fold, respectively (Fig.  3A) . Similarly, pGORF4 and pORF62 induced the expression of pORF4-CAT by three-and eight-fold, respectively. A six-fold stimulation of pORF68-CAT expression was observed with pORF62. Cotransfection of cells with pORF62 and pGORF4 induced the expression of HIV-LTR-CAT by five-and eight-fold, respectively (Fig. 3A) . We first tested the effect of pORF61 on pGORF4-and pORF62-induced trans-activation of pltk-CAT. Vero cells were cotransfected with pORF61 along with pltk-CAT and either pGORF4 or pORF62. ORF61 inhibited the trans-activation of pltk-CAT by pORF62 and pGORF4 by 100 and 77%, respectively (Fig.  3B, columns 1 and 2) . pORF61 was able to down-regulate the activation of pltk-CAT by VZV putative immediate-early genes but had no effect on the endogenous activity of pltk-CAT. Cotransfection with ORF61 resulted in CAT activity levels which were almost identical to the basal level of expression of the target gene in the absence of effector plasmids, i.e., pGORF4 and pORF62. ORF61 also inhibited the synergistic trans-activation of pltk-CAT by pGORF4 and pORF62 by 63% (Fig. 3B, column 3 ). Similarly, we tested the effect of pORF61 on VZV immediate-early and late promoter-CAT constructs. pORF61 inhibited pORF62, and pGORF4 induced trans-activation of pORF4-CAT by 78 and 59%, respectively (Fig. 3B, columns 4 and 6) . Similarly, pORF61 inhibited pORF62-mediated trans-activation of pORF68-CAT by 78% (Fig. 3B, column 6 ). The transrepressing effect of ORF61 on pGORF4-mediated transactivation of pORF68-CAT could not be assessed because pGORF4 stimulated the expression of pORF68-CAT by only twofold.
It has been previously reported that VZV can stimulate the expression of the (HIV LTR) (18) . To observe the effect of pORF61 on trans-activation of a non-VZV target, cotransfection assays were performed in the presence of pORF61, HIV-LTR-CAT, and pGORF4 or pORF62. pORF61 downregulated the pORF62-and pGORF4-mediated expression of HIV-LTR-CAT by 97 and 84%, respectively (Fig. 3B , columns 7 and 8). In addition, plasmid p29-A61, which contains a deletion in its ORF61 gene, thus leaving a functional ORF60 gene, was not able to repress pGORF4-mediated trans-activation of pltk-CAT. pGORF4 stimulated the transactivation of pltk-CAT (Fig. 4; compare lanes 1 and 2) , and p29 down-regulated this increased expression of pltk-CAT (lanes 2 and 3). As shown in lane 4, cotransfection of Vero cells with p29-A61 did not down-regulate pGORF4-mediated activation of pltk-CAT, thus proving that ORF61, and not ORF60, is associated with trans-repressive activity.
Effect of ORF61 on expression of heterologous promoters. To eliminate the possibility that pORF61 acts in a nonspecific fashion, Vero cells were cotransfected with either pSV2CAT (CAT construct driven by the SV40 promoter and enhancer sequences) or RSV-CAT (CAT cassette driven by the Rous sarcoma virus LTR). In these assays, ORF61 failed to repress the expression of both pSV2CAT (Fig. SA, lanes  1 and 2) and RSV-CAT (Fig. SA, lanes 3 and 4) . We also tested the effect of pORF61 on trans-activation of the HTLV-I and HIV LTRs by tax and tat genes, respectively. pSV2tat (carrying the HIV tat gene) activated the expression of the HIV-LTR-CAT construct (Fig. SB, lanes 1 and 2) . mass of 19 kDa. To prove that the pORF61 protein product is responsible for trans-repressor activity, we performed cotransfection assays in Vero cells, using pORF62 (pGi26) and pltk-CAT along with pORF61 or one of its deletion or insertion mutants. pORF62 enhanced the expression of pltk-CAT (Fig. 7A, lanes 3 and 4) , whereas cotransfection with pORF61 repressed the pORF62-enhanced expression of pltk-CAT (compare lanes 4 and 5). In contrast, all mutants of pORF61 lost their ability to down-regulate the pORF62-enhanced expression of pltk-CAT (lanes 6 to 8). Lane 1 shows the background CAT activity of mock-transfected cells, and lane 2 shows the CAT activity obtained when Vero cells were transfected with pSV2CAT as a positive control. Similarly, pGORF4 activated the expression of pltk-CAT (Fig. 7B, lanes 1 and 2) . Cotransfection with pORF61 down-regulated the pGORF4-induced expression of pltk-CAT (lanes 2 and 3), whereas both deletion (pORF61-A2) and insertion (pORF61-i3) mutants of ORF61 were unable to repress the activation of pltk-CAT by pGORF4 (lane 4 and 5).
ORF61 inhibits transcription at the RNA level. To determine whether the trans-repression of CAT activity by pORF61 occurs at the RNA level, CAT mRNA levels were quantitated by slot blot analysis. pltk-CAT showed a low basal level of CAT mRNA (Fig. 8) , but upon cotransfection with pORF62 (pGi26), an increased level of CAT mRNA could be detected. The addition of pORF61 in this cotransfection assay along with pltk-CAT and pORF62 (pGi26) resulted in down-regulation of the CAT mRNA level which almost matched the basal level obtained in a transfection assay with pltk-CAT alone. In contrast, the addition of pORF61 deletion or insertion mutants instead of pORF61 did not decrease pORF62-induced expression of CAT mRNA, thus demonstrating the role of ORF61 protein in transrepressing at the level of RNA. Therefore, repression occurred either at the level of transcription or at the level of mRNA stability.
RNA analysis of gene 61. The published sequence of VZV (4) reveals that ORF61 spans 1.4 kb from the start codon to the stop codon and has a putative polyadenylation signal 80 bp downstream of the stop codon. Northern hybridization analysis using a 32P-labeled 687-bp internal fragment of ORF61 as a probe and total RNA from VZV-infected MRC-5 cells revealed a single band of 1.8 kb (Fig. 9A) . To map the start site of the ORF61 gene, primer extension analysis was performed, using total RNA from VZV-infected MRC-5 cells and a synthetic oligonucleotide primer whose sequence and location are described in Materials and Methods. Primer extension analysis positioned the mRNA start site at 69 bp upstream of the AUG codon (Fig. 9B) (17) . To characterize this VZV-encoded trans-repressor, we constructed plasmids carrying the putative promoter and regulatory regions of the VZV tk, ORF4, and gpl genes. The reporter plasmids were used in cotransfection assays with putative immediate-early trans-acting genes pGORF4 and pORF62. ORF61 reproducibly down-regulated the ability of these trans-activators to function. To prove the specificity of ORF61-mediated transrepression, we used three criteria. First, pORF61 did not inhibit the expression of pSV2CAT and RSV-CAT (Fig. 5A) . Second, it had no trans-repressing effect on the activation of the HTLV-I and HIV-1 LTRs by tax and tat genes, respectively (Fig. 5B) . Third, both deletion and insertion mutants of gene 61 lost their ability to trans-repress (Fig. 7) . By coupled in vitro transcription and translation, we have provided evidence that the insertion mutant of ORF61, in fact, makes a truncated protein. These results suggest that trans-repression requires the expression of the ORF61 gene and VZV putative immediate-early trans-activating proteins. We do not know whether the observed trans-repression of viral promoters is a direct or an indirect effect brought about by the ORF61 product. Our results indicate that the products of ORF4 and ORF62 may interact with the product of ORF61 to negatively regulate gene expression, since the latter has no direct effect on the basal level of promoter activity but, in contrast, acts to counteract the stimulatory effects of pGORF4 and pORF62. Interestingly, ORF61 is the HSV-1 ICPO homolog, as defined by gene location, sharing of a cysteine-rich putative zinc-binding finger in the amino-terminal region, and limited amino acid homology (4). Functionally, HSV-1 ICPO has been found to be a potent transactivator of many promoters (8, 9, 11, 27, 32, 34, 37, 42) . The mechanisms of action of ORF61 and ICPO have yet to be elucidated. Further, no trans-repressing activity has been associated with HSV-1 ICPO. To our knowledge, this is the first report regarding the identification of a viral gene which negatively regulates the expression of all sets of viral genes.
It has been shown that the HSV-1 immediate-early gene ICP27 protein product can trans-repress or trans-activate, depending on the presence of two other immediate-early trans-activating proteins, ICP4 and ICPO (41) . ICP27 significantly repressed the induction of HSV-1 tk, glycoprotein B, glycoprotein D, and glycoprotein C promoter-CAT constructs by ICPO and ICP4 (41) . Cotransfection of cells with ICP27 reduced the expression of each of these HSV-1 targets to the basal level seen in the absence of ICPO or ICP4. Therefore, VZV ORF61 seems to be functionally analogous to HSV-1 ICP27, except that repression with ORF61 in in vitro assays is more general and pronounced. HSV ICP4 has been shown to negatively autoregulate expression from its own promoter (reference 39a and references therein). Such a down-regulation differs from that of ORF61-mediated expression in that the ICP4 protein directly binds to its own promoter. A similar autorepression has been observed in the case of VSV putative immediate-early gene 62 (Sa) . Furthermore, mutational analysis of HSV-1 ICP4, HSV-1 ICP27, and adenovirus Ela genes has shown that the activator and repressor activities reside in different domains of these proteins.
There are three possible mechanisms to explain the transrepressive activity of the ORF61 gene product. The first is that the ORF61 protein directly binds to the promoter regions of target genes. The NH2-terminal region of the ORF61 protein product contains a number of cysteine resi-A 9 J. VIROL.
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on October 28, 2017 by guest http://jvi.asm.org/ Downloaded from dues which resemble metal-binding domains (4) . A putative zinc-binding finger similar to the predicted zinc fingers of the steroid/thyroid hormone receptor DNA-binding domain (7) can be seen in its amino-terminal region. All of these cysteines are conserved between HSV-1 ICPO and VZV ORF61. Since HSV-1 ICPO has not been shown to be a sequence-specific DNA-binding protein, a similar analogy can be extrapolated to ORF61. Therefore, it may be possible that ORF61, like HSV-1 ICPO, does not interact with DNA.
Adenovirus Ela also has a zinc-binding domain but does not bind to DNA in a sequence-specific manner on its own (25) . Instead, Ela requires a cellular protein, ATF-2, for binding to cyclic AMP-responsive sequences in the promoter region of the effector viral as well as cellular genes (26) . Similarly, HSV-1 ICPO also acts through ATF sequences to activate the expression of heterologous viral and cellular promoters (22a). Therefore, a second possibility is that the ORF61 protein product interacts with a cellular transcription factor or with a so-called adaptor or intermediary protein which interacts both with viral immediate-early genes and with the RNA polymerase II transcription machinery. A final possibility is that the ORF61 protein interacts with the ORF4 and ORF62 gene products. Interaction of the ORF61 product with ORF4 and ORF62 proteins or with the adaptor molecule is suggested by the fact that the ORF61 product has little or no ability on its own to trans-repress in cotransfection experiments but invariably requires the presence of pGORF4 and pORF62. Another suggestion supporting the model of protein-protein interaction comes from analysis of the predicted amino acid sequences of ORF4 and ORF62.
Both contain putative leucine zipper motifs which have been shown to be involved in protein-protein interaction. In the carboxy-terminal region of ORF4, a putative leucine zipper (L-L-C-L-L) in which leucines are repeated seven amino acids apart is seen. A similar leucine zipper region (with three consecutive leucine repeats) is also represented in the gene 62 protein. Although a typical leucine zipper consists of four to six leucine residues placed seven amino acids apart (23) , it has been shown that in the cyclic AMP response element-binding protein, the first three leucine residues are necessary for efficient protein-protein interaction (6) . If ORF61 acts by virtue of protein-protein interaction, it may involve domains that are structurally homologous rather than domains that show significant amino acid sequence homology, since the predicted protein products of ORF4 and ORF62 do not have significant amino acid homology.
The encoding by VZV of a potent trans-repressor raises several interesting questions about the link between ORF61-mediated repression and latency of VZV. Is the mechanism of trans-repression of immediate-early, early, and late gene promoters related to latent infection with VZV? At what stage of the viral life cycle is ORF61 protein expressed, and is it carried along with the virus during infection? Is this negative regulation of gene expression related to the low frequency of recurrent VZV infection and its difficult growth in cultured cells? Establishing such a link could help in determining the mechanisms that control gene expression during viral replication and latency.
